Startseite

Aktien

Enveric Biosciences

Nachrichten

Enveric Biosciences Aktie

Aktie

ISIN: US29405E5050 WKN: A41HB6 SYM: ENVB Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

6,7000

USD

-1,33 %

-0,0900 USD

Letzter Kurs 14:07:56 Nasdaq

Enveric Biosciences Aktie kaufen

Geldkurs

05.12.25

6,5700

USD

100 STK

Briefkurs

05.12.25

6,8000

USD

400 STK

Verkauf

Kauf

Hinweis
Verlängerte Handelszeiten
Ab sofort von 07:30 bis 23:00 Uhr

Neueste Nachrichten

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026” 04.12.25 · Business Wire (engl.) · Enveric Biosciences
Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates 26.11.25 · Business Wire (engl.) · Enveric Biosciences
Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results 14.11.25 · Business Wire (engl.) · Enveric Biosciences
Enveric Biosciences Announces Reverse Stock Split 23.10.25 · Business Wire (engl.) · Enveric Biosciences
Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance 16.10.25 · Business Wire (engl.) · Enveric Biosciences
Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal 15.10.25 · Business Wire (engl.) · Enveric Biosciences
Enveric Biosciences to Explore Digital Asset Treasury Opportunities 14.10.25 · Business Wire (engl.) · Enveric Biosciences
Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials 02.10.25 · Business Wire (engl.) · Enveric Biosciences
Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds 18.09.25 · Business Wire (engl.) · Enveric Biosciences
Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds 17.09.25 · Business Wire (engl.) · Enveric Biosciences
Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery 17.09.25 · Business Wire (engl.) · Enveric Biosciences
Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission 16.09.25 · Business Wire (engl.) · Enveric Biosciences

1
2
…
3

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th ... 104 Leser

Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results 104 Leser
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th ... 104 Leser
Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates 100 Leser

Enveric Biosciences CEO Issues Letter to Shareholders 196 Leser
Enveric Biosciences Participating in BIO-Europe Spring 176 Leser
Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent 152 Leser
Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic ... 144 Leser
Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules ... 144 Leser
Enveric Biosciences Announces Closing of $5 Million Public Offering 144 Leser
Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND ... 144 Leser
Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results 144 Leser
Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States ... 140 Leser
Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds 136 Leser